Dr. Jacqueline Lui, Managing Director of Eagle IP Ltd., gave a talk on 專利保護運用與案例 during the conference at 中國深圳南山數字文化產業基地.

我們過去活動

Recommended Insights

IP Strategies for the Newly Released Implementation Regulations of the 4th Amendment of the Chinese Patent Law: Part 2: Grace Period without Loss of Novelty

2024年2月7日
Background As mentioned in our earlier article, the Implementation Regulations of the Chinese Patent Law (“Regulations”, similar to the CFR in the US) were approved in November, and the CNIPA finally made public the full text of the Regulations just before the arrival of the New Year. At the same time, the CNIPA also released […]

China’s Supreme People’s Court (SPC) Hands Down First Patent Linkage Appeal Decision

2022年9月21日
China has been implementing a plethora of new laws and measures that are particularly favorable to drug companies, such as patent term extension and patent linkage.  Details of the new implementation measures for patent linkage (technically “early dispute resolution mechanisms for drug patents”) came into effect on July 4, 2021. At around the same time, […]

China’s Newest Examination Guidelines: Inventive Step for Biological / Life Science Inventions (Part III)

2021年4月30日
This is Part III of a three-part series summarizing the Examination Guidelines that were released by the CNIPA on January 15, 2021, one year to the date of Phase 1 of the US and China Economic and Trade Agreement. That agreement included specific provisions where China "shall permit pharmaceutical patent applicants to rely on supplemental […]

New Fee Standards Released for Chinese Patent Applications

2024年9月6日
Recently, the Chinese government issued four official notices introducing new fee standards and deduction rules for Chinese patent applications.1 These updates address international applications (PCT applications) and the Chinese national phase applications thereof, as well as patent term adjustment/extension (PTA/PTE). Please find our summary below: PCT application fee deduction rules   Application fee & extra […]
Top crossarrow-right